ArriVent BioPharma, Inc. Common Stock (AVBP)
Automate Your Wheel Strategy on AVBP
With Tiblio's Option Bot, you can configure your own wheel strategy including AVBP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AVBP
- Rev/Share 0.0
- Book/Share 5.9749
- PB 3.195
- Debt/Equity 0.0007
- CurrentRatio 14.343
- ROIC -0.3633
- MktCap 700512323.0
- FreeCF/Share -3.5279
- PFCF -5.8575
- PE -5.0772
- Debt/Assets 0.0006
- DivYield 0
- ROE -0.4929
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AVBP | Goldman | -- | Buy | -- | $33 | July 10, 2025 |
| Initiation | AVBP | B. Riley Securities | -- | Buy | -- | $37 | March 20, 2025 |
| Initiation | AVBP | Guggenheim | -- | Buy | -- | $45 | March 10, 2025 |
News
ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC) is projected to be in early 2026.
Read More
New Strong Sell Stocks for July 21st
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Negative
CDZI, AVBP and ACCO have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2025.
Read More
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients
Read More
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET.
Read More
ArriVent BioPharma Reports First Quarter 2025 Financial Results
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first …
Read More
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D.
Read More
About ArriVent BioPharma, Inc. Common Stock (AVBP)
- IPO Date 2024-01-26
- Website https://www.arrivent.com
- Industry Biotechnology
- CEO Zhengbin Yao
- Employees 52